期刊文献+

Ⅲ期卵巢上皮癌术前CA125水平与手术彻底性的关系 被引量:5

The Predictive Value of Preoperative Serum CA125to Optimal Tumor Cytoreduction in Stage Ⅲ Epithelial Ovarian Carcinoma
暂未订购
导出
摘要 目的:探讨Ⅲ期卵巢上皮癌术前CA125水平与手术彻底性的关系。方法:回顾手术治疗的86例Ⅲ期卵巢上皮癌患者术前CA125水平以及相应的手术彻底性临床资料,应用受试者工作特征(ROC)曲线探讨术前CA125水平与手术彻底性的关系,并确定作为预测手术彻底性诊断界点的CA125水平。结果:86例患者中46例(53.5%)完成了满意的肿瘤减灭术(残留肿瘤最大径≤2cm);随着CA125水平增加肿瘤减灭术满意性下降;CA125预测手术彻底性的诊断界点是750μ/ml,术前CA125<750μ/ml的患者中34例(63.4%)完成了满意的减灭术,而术前CA125>750μ/ml的患者中12例(35.3%)完成了满意的减灭术;以超过750μ/ml无法完成满意的减灭术为阳性,敏感性64.7%,特异性65.4%,阳性预测值55.0%,阴性预测值73.9%。结论:Ⅲ期卵巢上皮癌患者术前CA125超过750μ/ml者,须充分评估手术可行性。 Objective:To assess the predictive value of preoperative serum CA125to opti-mal tumor cytoreduction in stageⅢepithelial ovarian carcinoma.Methods :We retrospectively re-view the preoperative serum CA125values and operation records of86consecutive patients with stageⅢepithelial ovarian carcinoma and determined the CA125level with the maximal prognos-tic power in predicting optimal versus suboptimal cytoreduction by means of receiver operating characteristic curve(ROC curve).Results:The optimal cytoreduction(diameter of largest residual tumor nodule≤2cm)was obtained in46patients(53.3%).The probability of performing optimal cytoreduction decreased with increasing CA125levels.A preoperative CA125level of750u/ml was identified as the value with the most predictive power.Optimal cytoreduction was achieved in34(63.4%)cases with CA125less than750u/ml compared to12(35.3%)cases with CA125greater than750u/ml.Defining suboptimal cytoreduction cases with CA125greater than750u/ml as positive,the sensitivity,specificity,positive predictive value and negative predictive value were respectively64.7%,65.4%,55%and73.9%.Conclusion:Those patients of stageⅢepithelial o-varian carcinoma with preoperative CA125greater than750u/ml should be fully assessed the probability of optimal cytoreduction preoperatively.
作者 赵晓东 张毅
机构地区 北京医院妇产科
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2003年第10期718-720,共3页 Chinese Journal of Clinical Oncology
关键词 卵巢上皮癌 CA125 肿瘤细胞减灭术 ROC曲线 Epithelial ovarian carcinoma CA125Cytoreduction ROC curve
  • 相关文献

参考文献1

  • 1顾学箕主编.预防医学[M].北京:人民卫生出版社,1992.128~138.

同被引文献52

  • 1赵晓东,张毅,张巧.高CA125的Ⅲ期卵巢上皮癌新辅助化疗的探讨[J].中国肿瘤临床,2005,32(5):264-268. 被引量:6
  • 2Balat O. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary[J]. Eur J Gynaecol Oncol, 2004, 25 (2): 195~196
  • 3Shibata K, Kikkawa F, Suzuki Y, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: survival benefit and prognostic factors[J]. Int J Gynecol Cancer, 2003, 13(3):587~592
  • 4Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma [J]. Gynecol Oncol,2001, 82(2): 532~537
  • 5Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery foradvanced ovarian carcinoma during the platinum era: a meta-analysis [J]. J Clin Oncol, 2002,20(5): 1248~1259
  • 6Kuhn W, Rutke S, Spathe K, et al. Neoadjvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in Intenational Federation of Gynecology and Obstetrics stage Ⅲ c ovarian carcinoma [J]. Cancer, 2001, 92 (10):2585 ~2591
  • 7Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer[J]. Gynecol Oncol, 1991, 42(2): 146~150
  • 8Vergote I, De Wever I, Tjalma W, et al. Neoadjvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:a retrospective analysis of 285 patients [J]. Gynecol Oncol, 1998,71(3): 431~436
  • 9Ansquer Y, Leblanc E, Clough K, et al. Neoadjvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study [J]. Cancer, 2001, 91(12): 2329~2334
  • 10Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjvant chemotherapy for advanced ovarian cancer: long-term survival[J].Gynecol Oncol, 1999, 729(1): 93~99

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部